Drug Profile
SAR 438544
Alternative Names: SAR438544Latest Information Update: 27 Jul 2017
Price :
$50
*
At a glance
- Originator Sanofi
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 1 diabetes mellitus
Most Recent Events
- 09 Jun 2017 Adverse events, pharmacokinetics and pharmacodynamics data from a phase I trial in Type-1 diabetes mellitus presented at the 77th Annual Scientific Sessions of the American Diabetes Association (ADA-2017)
- 01 Aug 2016 Discontinued - Phase-I for Type-1 diabetes mellitus in USA (SC)
- 24 Dec 2015 Sanofi plans a phase I trial for Type-1 diabetes mellitus (Treatment-experienced) in USA (SC) (NCT02635243)